Arvinas will present preclinical data on ARV-393's potential in lymphoma treatment at the AACR Annual Meeting. Quiver AI Summary. Arvinas, Inc., a biotechnology company focused on targeted protein ...

ARV-393 in combination with SOC chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone [R-CHOP]), induced significantly greater tumor growth inhibition compared with ...

Arvinas Inc. – Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 ...

Arvinas Presents Promising Preclinical Data for BCL6 Degrader ARV-393 in Lymphoma Treatment. A biopharma executive in a meeting room discussing the clinical-stage of a new therapy.